21. Odpornost glioblastoma na radioterapijo : vpliv rakavih matičnih celic in mikroo[ko]lja tumorjaBarbara Breznik, Bernarda Majc, Anamarija Habič, Urška Ušeničnik, Andrej Porčnik, Roman Bošnjak, Jernej Mlakar, Marija Skoblar Vidmar, Tanja Jesenko, Maja Čemažar, Tamara Lah Turnšek, Metka Novak, 2022, objavljeni znanstveni prispevek na konferenci (vabljeno predavanje) Povzetek: Glioblastom je najpogostejši možganski tumor pri odraslih z zelo slabo prognozo preživetja bolnikov. Ta je posledica odpornosti glioblastoma na standardno zdravljenje, ki vključuje radioterapijo in kemoterapijo. Z namenom načrtovanja učinkovitejših pristopov zdravljenja preučujemo biološke mehanizme odpornosti glioblastoma na radioterapijo s poudarkom na mikrookolju tumorja in rakavih matičnih celicah. V predkliničnih raziskavah uporabljamo napredne in personalizirane celične modele, ki posnemajo mikrookolje tumorja v bolnikih in z večjo natančnostjo napovedo odziv bolnika na zdravljenje. Hkrati so takšni modeli pomembni za testiranje novih pristopov za zdravljenje kot je imunoterapija.
Ključne besede: glioblastom, mikrookolje, organoidi, možganski rak, možganski tumor, onkologija
Objavljeno v DiRROS: 16.06.2022; Ogledov: 620; Prenosov: 199
 Celotno besedilo (89,78 KB) |
22. P14/ARF-positive malignant pleural mesothelioma : ǂa ǂphenotype with distinct immune microenvironmentFederica Pezzuto, Francesca Lunardi, Luca Vedovelli, Francesco Fortarezza, Loredana Urso, Federica Grosso, Giovanni Luca Ceresoli, Izidor Kern, Gregor Vlačić, Fiorella Calabrese, 2022, izvirni znanstveni članek Povzetek: Introduction: The CDKN2A gene plays a central role in the pathogenesis of malignant pleural mesothelioma (MPM). The gene encodes for two tumor suppressor proteins, p16/INK4A and p14/ARF, frequently lost in MPM tumors. The exact role of p14/ARF in MPM and overall its correlation with the immune microenvironment is unknown. We aimed to determine whether there is a relationship between p14/ARF expression, tumor morphological features, and the inflammatory tumor microenvironment. Methods: Diagnostic biopsies from 76 chemo-naive MPMs were evaluated. Pathological assessments of histotype, necrosis, inflammation, grading, and mitosis were performed. We evaluated p14/ARF, PD-L1 (tumor proportion score, TPS), and Ki-67 (percentage) by immunohistochemistry. Inflammatory cell components (CD3+, CD4+, CD8+ T lymphocytes; CD20+ B-lymphocytes; CD68+ and CD163+ macrophages) were quantified as percentages of positive cells, distinguishing between intratumoral and peritumoral areas. The expression of p14/ARF was associated with several clinical and pathological characteristics. A random forest-based machine-learning algorithm (Boruta) was implemented to identify which variables were associated with p14/ARF expression. Results: p14/ARF was evaluated in 68 patients who had a sufficient number of tumor cells. Strong positivity was detected in 14 patients (21%) (11 epithelioid and 3 biphasic MPMs). At univariate analysis, p14/ARF-positive epithelioid mesotheliomas showed higher nuclear grade (G3) (p = 0.023) and higher PD-L1 expression (≥50%) (p = 0.042). The percentages of CD4 and CD163 in peritumoral areas were respectively higher and lower in p14/ARF positive tumors but did not reach statistical significance with our sample size (both p = 0.066). The Boruta algorithm confirmed the predictive value of PD-L1 percentage for p14/ARF expression in all histotypes. Conclusions: p14/ARF-positive epithelioid mesotheliomas may mark a more aggressive pathological phenotype (higher nuclear grade and PD-L1 expression). Considering the results regarding the tumor immune microenvironment, p14/ARF-negative tumors seem to have an immune microenvironment less sensitive to immune checkpoint inhibitors, being associated with low PD-L1 and CD4 expression, and high CD163 percentage. The association between p14/ARF-positive MPMs and PD-L1 expression suggests a possible interaction of the two pathways. Confirmation of our preliminary results could be important for patient selection and recruitment in future clinical trials with anticancer immunotherapy.
Ključne besede: lung -- cytology -- pathology, neoplasms, malignant mesothelioma, malignant pleural mesothelioma, tumor microenvironment
Objavljeno v DiRROS: 30.05.2022; Ogledov: 826; Prenosov: 527
Celotno besedilo (13,14 MB)
Gradivo ima več datotek! Več... |
23. |
24. Zbornik2019, zbornik strokovnih ali nerecenziranih znanstvenih prispevkov na konferenci Povzetek: Kolposkopija še ostaja zelo pomemben del presejalnih programov raka materničnega vratu. Vloga in pomen kakovostne kolposkopske obravnave bosta še izrazitejši v bližnji prihodnosti, ko bodo na preizkušnji podaljšani intervali in HPV problematika v triažnem in morda presejalnem pomenu. Te spremembe sicer veliko obetajo, a hkrati zahtevajo pogoje za kakovostno opravljanje kolposkopske dejavnost, ki se v Sloveniji vse prepočasi uveljavljajo. V pričujoči publikaciji najpomembnejši slovenski strokovnjati tega področja predstavljajo najnovejša spoznanja in smernice za presejanje in diagnostiko bolezni.
Ključne besede: ginekologija, onkologija, humani papiloma virus, presejanje, bris materničnega vratu, predrakave spremembe, rodila, tumor, klasifikacija, vulva, nosečnost, pojasnilna dolžnost, zborniki, elektronske knjige
Objavljeno v DiRROS: 17.04.2020; Ogledov: 4391; Prenosov: 798
Celotno besedilo (16,91 MB) |
25. |
26. |
27. |
28. |
29. Predlog priporočil za celostno rehabilitacijo otrok z možganskim tumorjemLidija Kitanovski, Katja Groleger Sršen, Nataša Kos, Barbara Faganel Kotnik, Primož Kotnik, Ivana Kreft, Lorna Zadravec-Zaletel, Saba Battelino, 2019, objavljeni strokovni prispevek na konferenci (vabljeno predavanje) Ključne besede: pediatrija, onkologija, možganski tumor, otroška onkologija
Objavljeno v DiRROS: 18.09.2019; Ogledov: 2285; Prenosov: 621
Celotno besedilo (101,62 KB) |
30. |
